NSE: LAURUSLABS | BSE: 540222

Mid-range Performer

Download real time

877.95 3.65 (0.42%)

99.33% Gain from 52W Low

3.3M NSE+BSE Volume

NSE 14 Oct, 2025 3:31 PM (IST)

47,393.9

Market Cap

High in industry

1.3

Beta 1Year

Very High Volatility

Board Meeting

The next board meeting for Laurus Labs Ltd. is on 23 Oct 2025 for the purpose of Quarterly Results & Interim Dividend See details

Laurus Labs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LAURUSLABS, BSE:540222 Laurus Labs Ltd.

Search Inside the pdf :

Laurus Labs Ltd.

01 Aug 2025

877.95

0.42%

Solid Q1FY26 execution underpins confidence in CDMO-led growth strategy

Sell: Laurus Labs Ltd.

Deven Choksey

Revenue: Consolidated revenue for the quarter increased by 31.4% YoY (-8.8% QoQ) to INR 15,696 Mn., significant beat on our estimates (+15.0%), driven by strong outperformance in the Custom Synthesis and the Generic FDF segment.

Number of FII/FPI investors increased from 259 to 293 in Jun 2025 qtr.

Laurus Labs Ltd.

20 May 2025

877.95

0.42%

Laurus Labs Ltd

Buy: Laurus Labs Ltd.

AUM Capital

Laurus Labs Ltd (Laurus) was incorporated in the year 2005 as an Anti-Retroviral (ARV) Active Pharmaceutical Ingredient (API) company. (ARV drugs are medications used to treat HIV infection and prevent its progression). Later, it diversified its operations by entering into Formulations and Contract Development Manufacturing Operations (CDMO) services to become an integrated pharma company. Currently, Laurus's...

Laurus Labs Ltd. has gained 83.31% in the last 1 Year

Laurus Labs Ltd.

25 Apr 2025

877.95

0.42%

Laurus Labs (HOLD): Visibility of Operating Leverage

Hold: Laurus Labs Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Revenue/EBITDA/PAT exceeded our estimates by 8.4%/32.6%/110.3%; EBITDA margin surpassed our estimate by 440 bps

Laurus Labs Ltd. has gained 83.31% in the last 1 Year

Laurus Labs Ltd.

24 Apr 2025

877.95

0.42%

FDF/CDMO drives earnings; ends FY25 on strong note

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab (LAURUS) delivered a second consecutive quarter with betterthan-expected performance, led by healthy traction in the Formulation (FDF)/API segment. Despite softer-than-expected performance in the CDMO business during 4QFY25, the quarterly sales run rate continued its uptrend.

Laurus Labs Ltd. has gained 83.31% in the last 1 Year

Laurus Labs Ltd.

27 Jan 2025

877.95

0.42%

Laurus Labs (SELL): Margin guidance shifted from 20% to closer to 20% for FY25E

Sell: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Revenue/EBITDA/PAT exceeded our estimates by 10.5%/46.6%/227%. EBITDA margin surpassed our estimate by 500bps

Laurus Labs Ltd. has gained 44.91% in the last 6 Months

Laurus Labs Ltd.

25 Jan 2025

877.95

0.42%

Beat on earnings; green shoots visible

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab (LAURUS) significantly beat our earnings estimates in 3QFY25, led by a scale-up in the CDMO segment. Commercial supplies (including launch quantities) led to strong 89% YoY growth in CDMO sales for the quarter.

Number of FII/FPI investors increased from 259 to 293 in Jun 2025 qtr.

Laurus Labs Ltd.

25 Oct 2024

877.95

0.42%

Laurus Labs (SELL): Another weak quarter

Sell: Laurus Labs Ltd.

BOB Capital Markets Ltd.

Earnings miss for 2Q on our and street estimates on all fronts. Revenue/PAT came short of consensus estimates by -5%/39%

Laurus Labs Ltd. is trading below its 30 day SMA of 882.0

Laurus Labs Ltd.

24 Oct 2024

877.95

0.42%

In-line quarter; CDMO traction to pick up in 2HFY25

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab (LAURUS) delivered largely in-line operational performance for 2QFY25. It witnessed an improving traction in the CDMO business, with a 33%/44% YoY/QoQ jump in sales for 2QFY25.